| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 102 | 2024 | 943 | 8.760 |
Why?
|
| Skin Neoplasms | 64 | 2024 | 860 | 5.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 39 | 2024 | 1244 | 2.830 |
Why?
|
| Proto-Oncogene Proteins B-raf | 21 | 2024 | 193 | 2.190 |
Why?
|
| Antineoplastic Agents | 25 | 2019 | 1714 | 1.670 |
Why?
|
| Ipilimumab | 16 | 2021 | 63 | 1.650 |
Why?
|
| Imidazoles | 8 | 2024 | 206 | 1.370 |
Why?
|
| Antibodies, Monoclonal | 13 | 2019 | 1026 | 1.350 |
Why?
|
| Pyrimidinones | 9 | 2024 | 51 | 1.100 |
Why?
|
| CTLA-4 Antigen | 5 | 2018 | 61 | 1.090 |
Why?
|
| Pyridones | 8 | 2024 | 118 | 1.010 |
Why?
|
| alpha-MSH | 6 | 2024 | 17 | 1.010 |
Why?
|
| Melanoma, Experimental | 6 | 2024 | 35 | 0.990 |
Why?
|
| Lipids | 4 | 2011 | 522 | 0.910 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2024 | 544 | 0.860 |
Why?
|
| Oximes | 5 | 2024 | 55 | 0.830 |
Why?
|
| Sulfonamides | 9 | 2017 | 270 | 0.820 |
Why?
|
| DNA, Recombinant | 4 | 2011 | 105 | 0.820 |
Why?
|
| Indoles | 8 | 2017 | 191 | 0.790 |
Why?
|
| Disease-Free Survival | 26 | 2019 | 880 | 0.780 |
Why?
|
| Mutation | 22 | 2024 | 5905 | 0.780 |
Why?
|
| Aged | 71 | 2024 | 19722 | 0.780 |
Why?
|
| Neoplasm Metastasis | 20 | 2016 | 706 | 0.770 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2020 | 115 | 0.750 |
Why?
|
| Neoplasm Staging | 27 | 2021 | 1275 | 0.730 |
Why?
|
| Positron-Emission Tomography | 5 | 2018 | 306 | 0.710 |
Why?
|
| Middle Aged | 76 | 2024 | 26763 | 0.690 |
Why?
|
| Interleukin-2 | 12 | 2019 | 244 | 0.690 |
Why?
|
| Aged, 80 and over | 39 | 2024 | 6558 | 0.680 |
Why?
|
| Naphthoquinones | 3 | 2014 | 8 | 0.680 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2014 | 91 | 0.670 |
Why?
|
| Lactams | 5 | 2023 | 19 | 0.640 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2016 | 147 | 0.630 |
Why?
|
| Adult | 69 | 2024 | 29543 | 0.590 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2009 | 247 | 0.570 |
Why?
|
| HLA-B7 Antigen | 2 | 2011 | 4 | 0.570 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 509 | 0.560 |
Why?
|
| MAP Kinase Kinase 1 | 5 | 2020 | 42 | 0.550 |
Why?
|
| Sentinel Lymph Node Biopsy | 9 | 2019 | 65 | 0.540 |
Why?
|
| Molecular Targeted Therapy | 7 | 2024 | 375 | 0.500 |
Why?
|
| Male | 78 | 2024 | 61565 | 0.470 |
Why?
|
| Dacarbazine | 12 | 2012 | 96 | 0.470 |
Why?
|
| Humans | 109 | 2024 | 125356 | 0.450 |
Why?
|
| Immunotherapy | 7 | 2020 | 678 | 0.450 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2017 | 733 | 0.450 |
Why?
|
| Female | 80 | 2024 | 66820 | 0.450 |
Why?
|
| Treatment Outcome | 37 | 2019 | 12287 | 0.440 |
Why?
|
| Paclitaxel | 4 | 2012 | 130 | 0.430 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 114 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2019 | 1065 | 0.430 |
Why?
|
| Radiopharmaceuticals | 5 | 2024 | 168 | 0.410 |
Why?
|
| MAP Kinase Kinase 2 | 3 | 2020 | 11 | 0.370 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 71 | 0.370 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2021 | 128 | 0.360 |
Why?
|
| Tissue Distribution | 8 | 2024 | 391 | 0.350 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 254 | 0.350 |
Why?
|
| Oligosaccharides | 2 | 2008 | 75 | 0.350 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2023 | 49 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2096 | 0.340 |
Why?
|
| Gallium Radioisotopes | 2 | 2020 | 7 | 0.330 |
Why?
|
| Mucous Membrane | 2 | 2024 | 89 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2019 | 240 | 0.320 |
Why?
|
| DNA | 2 | 2006 | 1621 | 0.320 |
Why?
|
| Vitiligo | 1 | 2009 | 7 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 493 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2015 | 57 | 0.310 |
Why?
|
| Survival Rate | 14 | 2017 | 2050 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2008 | 216 | 0.310 |
Why?
|
| Benzamides | 3 | 2014 | 110 | 0.300 |
Why?
|
| Sentinel Lymph Node | 2 | 2019 | 9 | 0.290 |
Why?
|
| Disease Progression | 11 | 2021 | 2084 | 0.290 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 505 | 0.290 |
Why?
|
| Glucuronidase | 1 | 2007 | 30 | 0.280 |
Why?
|
| Pyrimidines | 3 | 2015 | 377 | 0.270 |
Why?
|
| Tumor Escape | 1 | 2007 | 63 | 0.270 |
Why?
|
| Plasmids | 2 | 2011 | 513 | 0.270 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 3 | 2022 | 3 | 0.270 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 730 | 0.250 |
Why?
|
| Diphosphonates | 1 | 2006 | 38 | 0.250 |
Why?
|
| Survival Analysis | 10 | 2019 | 1495 | 0.240 |
Why?
|
| Dendritic Cells | 2 | 2008 | 414 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 4 | 2012 | 344 | 0.230 |
Why?
|
| Lutetium | 1 | 2024 | 1 | 0.230 |
Why?
|
| Cell Line, Tumor | 9 | 2024 | 3420 | 0.230 |
Why?
|
| Dasatinib | 1 | 2024 | 41 | 0.220 |
Why?
|
| Ibuprofen | 1 | 2024 | 40 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2017 | 1157 | 0.220 |
Why?
|
| Liposomes | 4 | 2013 | 188 | 0.220 |
Why?
|
| Double-Blind Method | 10 | 2019 | 1634 | 0.220 |
Why?
|
| Radiosurgery | 2 | 2018 | 111 | 0.220 |
Why?
|
| Interferon-alpha | 6 | 2012 | 241 | 0.220 |
Why?
|
| beta 2-Microglobulin | 1 | 2003 | 34 | 0.210 |
Why?
|
| Brain Neoplasms | 4 | 2018 | 1315 | 0.210 |
Why?
|
| Young Adult | 17 | 2021 | 9061 | 0.210 |
Why?
|
| Receptor, Melanocortin, Type 1 | 2 | 2022 | 6 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2019 | 45 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2010 | 74 | 0.200 |
Why?
|
| Uveal Neoplasms | 2 | 2013 | 59 | 0.200 |
Why?
|
| Sesquiterpenes | 1 | 2002 | 25 | 0.200 |
Why?
|
| Tretinoin | 2 | 2023 | 118 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 3 | 2013 | 314 | 0.200 |
Why?
|
| Piperazines | 2 | 2014 | 242 | 0.190 |
Why?
|
| Vinblastine | 6 | 2012 | 55 | 0.190 |
Why?
|
| Azetidines | 3 | 2019 | 57 | 0.190 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2021 | 20 | 0.190 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 128 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 669 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 146 | 0.180 |
Why?
|
| Albumins | 3 | 2024 | 93 | 0.180 |
Why?
|
| Lymph Node Excision | 3 | 2016 | 165 | 0.180 |
Why?
|
| B7-H1 Antigen | 2 | 2019 | 120 | 0.180 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 440 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1692 | 0.180 |
Why?
|
| Time Factors | 9 | 2021 | 6311 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2009 | 69 | 0.170 |
Why?
|
| Cisplatin | 6 | 2012 | 250 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 7 | 2024 | 4423 | 0.170 |
Why?
|
| Peptides, Cyclic | 1 | 2020 | 55 | 0.170 |
Why?
|
| Piperidines | 3 | 2019 | 208 | 0.170 |
Why?
|
| Infusions, Intravenous | 5 | 2014 | 554 | 0.170 |
Why?
|
| Acetates | 1 | 2020 | 73 | 0.170 |
Why?
|
| Signal Transduction | 2 | 2012 | 4595 | 0.170 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 1534 | 0.170 |
Why?
|
| Adolescent | 18 | 2021 | 19429 | 0.170 |
Why?
|
| Yttrium Radioisotopes | 1 | 2019 | 19 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 2 | 2021 | 381 | 0.160 |
Why?
|
| Animals | 16 | 2024 | 34319 | 0.160 |
Why?
|
| Nomograms | 1 | 2019 | 37 | 0.160 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2009 | 48 | 0.160 |
Why?
|
| Cancer Vaccines | 2 | 2011 | 177 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 61 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 914 | 0.150 |
Why?
|
| Mice | 11 | 2024 | 17750 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2011 | 206 | 0.140 |
Why?
|
| Gene Amplification | 2 | 2020 | 236 | 0.140 |
Why?
|
| Prognosis | 9 | 2020 | 4686 | 0.140 |
Why?
|
| Lymphatic Metastasis | 6 | 2016 | 418 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 234 | 0.130 |
Why?
|
| Antibodies | 1 | 2018 | 374 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2006 | 12 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 280 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 4 | 2020 | 163 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 1118 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1756 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 215 | 0.120 |
Why?
|
| Neoplasms | 3 | 2024 | 2799 | 0.120 |
Why?
|
| Retrospective Studies | 13 | 2019 | 16369 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 5171 | 0.110 |
Why?
|
| Decision Making | 1 | 2019 | 657 | 0.110 |
Why?
|
| Genetic Therapy | 2 | 2011 | 688 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 2520 | 0.110 |
Why?
|
| Lymphocyte Count | 3 | 2011 | 118 | 0.110 |
Why?
|
| Erythrocyte Indices | 1 | 2013 | 14 | 0.110 |
Why?
|
| Blood Cell Count | 1 | 2013 | 69 | 0.110 |
Why?
|
| United States | 8 | 2021 | 10908 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2017 | 73 | 0.110 |
Why?
|
| Sunlight | 1 | 2013 | 24 | 0.110 |
Why?
|
| Fatigue | 3 | 2011 | 188 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 101 | 0.100 |
Why?
|
| Vincristine | 1 | 2013 | 191 | 0.100 |
Why?
|
| Thrombocytopenia | 3 | 2011 | 225 | 0.100 |
Why?
|
| Side-Population Cells | 1 | 2012 | 12 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2019 | 3431 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 681 | 0.100 |
Why?
|
| RNA, Neoplasm | 2 | 2010 | 140 | 0.100 |
Why?
|
| Inflammation | 1 | 2019 | 1445 | 0.100 |
Why?
|
| Demography | 1 | 2012 | 238 | 0.090 |
Why?
|
| Genes, ras | 1 | 2012 | 100 | 0.090 |
Why?
|
| Drug Approval | 1 | 2011 | 43 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 78 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2023 | 107 | 0.090 |
Why?
|
| Apoptosis | 3 | 2014 | 1818 | 0.090 |
Why?
|
| Nausea | 2 | 2009 | 84 | 0.090 |
Why?
|
| GTP Phosphohydrolases | 3 | 2020 | 147 | 0.090 |
Why?
|
| Antigens, CD | 2 | 2010 | 430 | 0.090 |
Why?
|
| Quality of Life | 2 | 2017 | 1908 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 325 | 0.090 |
Why?
|
| Injections, Intralesional | 2 | 2009 | 48 | 0.090 |
Why?
|
| Hexanones | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2018 | 725 | 0.090 |
Why?
|
| Immunity | 1 | 2011 | 192 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 69 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2020 | 4828 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2010 | 18 | 0.080 |
Why?
|
| Albumin-Bound Paclitaxel | 1 | 2010 | 3 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 1982 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2007 | 130 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 1104 | 0.080 |
Why?
|
| Ear Neoplasms | 1 | 2008 | 13 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2012 | 875 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 825 | 0.080 |
Why?
|
| Oncolytic Virotherapy | 1 | 2009 | 85 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 772 | 0.070 |
Why?
|
| Peptides | 2 | 2024 | 812 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2008 | 101 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2008 | 13 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 2 | 2008 | 465 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2011 | 480 | 0.070 |
Why?
|
| Contusions | 1 | 2007 | 17 | 0.070 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 10 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2010 | 471 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 1240 | 0.070 |
Why?
|
| CD4 Antigens | 1 | 2007 | 57 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 45 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 625 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 1172 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2007 | 140 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 159 | 0.070 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2007 | 19 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 433 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 21 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1294 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2007 | 144 | 0.070 |
Why?
|
| Splenic Neoplasms | 1 | 2006 | 12 | 0.060 |
Why?
|
| Retinal Diseases | 1 | 2008 | 173 | 0.060 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2006 | 8 | 0.060 |
Why?
|
| Lymphangioma | 1 | 2006 | 24 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2007 | 174 | 0.060 |
Why?
|
| Menopause | 1 | 2006 | 75 | 0.060 |
Why?
|
| Extremities | 1 | 2006 | 83 | 0.060 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 5 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 65 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2013 | 683 | 0.060 |
Why?
|
| Nevus, Pigmented | 1 | 2005 | 32 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 358 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 378 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 50 | 0.060 |
Why?
|
| Genomics | 2 | 2024 | 1520 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2024 | 39 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 448 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2020 | 1538 | 0.060 |
Why?
|
| Imatinib Mesylate | 2 | 2014 | 45 | 0.060 |
Why?
|
| Azepines | 1 | 2024 | 64 | 0.050 |
Why?
|
| Patient Safety | 2 | 2019 | 398 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2012 | 366 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 62 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 1172 | 0.050 |
Why?
|
| Triazoles | 1 | 2024 | 140 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 384 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 316 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 1654 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2002 | 61 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2012 | 3056 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2014 | 6141 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2006 | 939 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2002 | 91 | 0.050 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 7 | 0.040 |
Why?
|
| Receptor, Notch2 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2020 | 92 | 0.040 |
Why?
|
| North America | 1 | 2021 | 243 | 0.040 |
Why?
|
| Diamines | 1 | 2020 | 8 | 0.040 |
Why?
|
| Fever | 2 | 2012 | 300 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 2909 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 292 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 283 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 445 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2019 | 295 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2018 | 192 | 0.040 |
Why?
|
| Fluorescence | 1 | 2018 | 96 | 0.040 |
Why?
|
| Exons | 2 | 2014 | 802 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 413 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2880 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 204 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1362 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2017 | 20 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2002 | 1399 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2020 | 306 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2011 | 408 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2017 | 68 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2010 | 2813 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 404 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 89 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 1316 | 0.030 |
Why?
|
| Kidney | 1 | 2022 | 1363 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 375 | 0.030 |
Why?
|
| Taxoids | 1 | 2014 | 67 | 0.030 |
Why?
|
| Gene Expression | 2 | 2012 | 1554 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 231 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1320 | 0.030 |
Why?
|
| Risk Factors | 4 | 2015 | 10298 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 1400 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 153 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 778 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1720 | 0.030 |
Why?
|
| Biological Therapy | 1 | 2012 | 21 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2012 | 78 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2011 | 26 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2013 | 220 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 351 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2011 | 144 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 1077 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 66 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 210 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 973 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1902 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 696 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 627 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 810 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4409 | 0.020 |
Why?
|
| Epitopes | 1 | 2011 | 433 | 0.020 |
Why?
|
| Hydrazines | 1 | 2009 | 30 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 28 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 630 | 0.020 |
Why?
|
| Disease Management | 1 | 2013 | 530 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2013 | 700 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 275 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1703 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2011 | 505 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 77 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 1189 | 0.020 |
Why?
|
| Constipation | 1 | 2009 | 114 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 241 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 12 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2008 | 77 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 23 | 0.020 |
Why?
|
| Forearm | 1 | 2008 | 45 | 0.020 |
Why?
|
| Interferons | 1 | 2008 | 126 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2008 | 145 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 49 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 173 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 746 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 989 | 0.020 |
Why?
|
| Pyridines | 1 | 2008 | 235 | 0.020 |
Why?
|
| Axilla | 1 | 2006 | 39 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 292 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2005 | 14 | 0.020 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2005 | 10 | 0.020 |
Why?
|
| PAX3 Transcription Factor | 1 | 2005 | 28 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 802 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2373 | 0.020 |
Why?
|
| Laparotomy | 1 | 2007 | 135 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 339 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2005 | 74 | 0.020 |
Why?
|
| Anemia | 1 | 2009 | 341 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 3106 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2007 | 192 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2007 | 310 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 1633 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2004 | 120 | 0.010 |
Why?
|
| Dementia | 1 | 2008 | 451 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 586 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 391 | 0.010 |
Why?
|
| Glucose | 1 | 2007 | 878 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2002 | 32 | 0.010 |
Why?
|
| Histamine | 1 | 2002 | 45 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 227 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2182 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 1244 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 2818 | 0.010 |
Why?
|
| Child | 2 | 2005 | 24613 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 7226 | 0.010 |
Why?
|